CMRX - キメリックス （Chimerix Inc.） キメリックスCMRXのチャート
CMRXの企業情報
| symbol | CMRx |
|---|---|
| 会社名 | Chimerix Inc. （キメリックス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 チメリックス（Chimerix Inc.）はバイオ医薬品会社である。同社は未充足の医療ニーズに対処する薬品の発見、開発、商業化を行う。同社のリード化合物brincidofovirは天然痘、アデノウイルス（AdV）、およびヒトヘルペスウイルスを含むデオキシリボ核酸（DNA）ウイルスの治療と予防のための経口および静脈内（IV）製剤として開発中である。同社はノロウイルスの予防、治療ためのCMX521の開発を進める。さらに、同社は治療法の乏しいあるいはないウイルス標的に集中するアクティブな発見プログラムがある。Brincidofovirは人間に感染できる5つのファミリーの二本鎖デオキシリボ核酸（dsDNA）ウイルスすべてに対してスペクトル抗ウイルス活性を示した研究用経口ヌクレオチド類似体である。brincidofovirの経口、IV製剤は活性な抗ウイルスをウイルス複製部位に直接送達する開発階段中である。 キメリックスは、米国のバイオ医薬品会社。経口抗ウイルス薬を発見、開発、商品化する。同社は独自の脂質技術を利用し、2種類のヌクレオチド化合物を開発。「Brincidofovir (CMX001)」は第3相臨床段階にある。「CMX157」は第1相臨床試験を終えた後、メルク・シャ―プ・アンド・ド―ム社へライセンス供与した。 |
| 本社所在地 | 2505 Meridian Parkway Suite 100 Durham NC 27713 USA |
| 代表者氏名 | Martha J. Demski マーサ・J・デムスキー |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 919-806-1074 |
| 設立年月日 | 36617 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2013年 |
| 従業員数 | 82人 |
| url | www.chimerix.com |
| nasdaq_url | https://www.nasdaq.com/symbol/cmrx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -75.05300 |
| 終値（lastsale） | 3.84 |
| 時価総額（marketcap） | 184420899.84 |
| 時価総額 | 時価総額（百万ドル） 172.89460 |
| 売上高 | 売上高（百万ドル） 4.72400 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） -1.86840 |
| 当期純利益 | 当期純利益（百万ドル） -74.98900 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Chimerix Inc revenues increased 13% to $2M. Net loss increased 12% to $38.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 21% to $25.2M (expense) General and administrative increase of 7% to $8.8M (expense). |
CMRXのテクニカル分析
CMRXのニュース
Insider Buying: Chimerix, Inc. (NASDAQ:CMRX) Director Acquires 1,500 Shares of Stock 2021/03/01 20:34:41 Watchlist News
Chimerix, Inc. (NASDAQ:CMRX) Director Robert J. Meyer acquired 1,500 shares of Chimerix stock in a transaction that occurred on Monday, March 1st. The shares were purchased at an average price of $9.80 per share, for a total transaction of $14,700.00. Following the transaction, the director now directly owns 15,000 shares in the company, valued at […]
Chimerix, Exclusive Worldwide Licensee of Cantex's Investigational Product, DSTAT, Has Announced Promising Topline Results from the First Cohort of a Randomized COVID-19 Clinical Trial - Stocks News Feed 2021/02/26 18:44:00 Stocks News Feed
WESTON, Fla., Feb. 26, 2021 /PRNewswire/ — Cantex Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing proprietary pharmaceuticals for the treatment of inflammatory lung diseases and cancer, today announced that Chimerix, Inc. (NASDAQ:CMRX), worldwide licensee of Cantex’s DSTAT investigational product, yesterday reported promising results of the first cohort of patients hospitalized with COVID-19-associated Acute Lung Injury (ALI),… Read More »Chimerix, Exclusive Worldwide Licensee of Cantex’s Investigational Product, DSTAT, Has Announced Promising Topline Results from the First Cohort of a Randomized COVID-19 Clinical Trial
Chimerix, Inc. to Host Earnings Call 2021/02/25 11:30:00 Yahoo Finance
NEW YORK, NY / ACCESSWIRE / February 25, 2021 / Chimerix, Inc. (NASDAQ:CMRX) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 25, 2021 at 8:30 AM Eastern Time.
The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout 2021/02/18 13:14:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 17) Advaxis, Inc. (NASDAQ: ADXS ) Angion Biomedica Corp (NASDAQ: ANGN ) Applied Genetic Technologies Corp (NASDAQ: AGTC ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Avanos Medical Inc (NYSE: AVNS ) Bausch Health Companies Inc (NYSE: BHC ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Bioatla Inc (NASDAQ: BCAB ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Chimerix Inc (NASDAQ: CMRX ) China Biologic Products Holdings Inc (NASDAQ: CBPO ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Endo International PLC (NASDAQ: ENDP ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Krystal Biotech Inc (NASDAQ: KRYS ) Laboratory Corp. of America Holdings (NYSE: LH ) Lucira Health Inc (NASDAQ: LHDX ) Nektar Therapeutics (NASDAQ: NKTR ) (announced a $150-million investment by SFJ Pharma for the Phase 2/3 registrational clinical study of BEMPEG plus Keytruda in patients with head and neck cancer) Oncolytics Biotech, Inc. (NASDAQ: ONCY ) (reacted to initiation of coverage by H.C.
The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs 2021/02/10 12:34:42 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 10) 9 Meters Biopharma Inc (NASDAQ: NMTR ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Amneal Pharmaceuticals Inc (NYSE: AMRX ) AngioDynamics, Inc. (NASDAQ: ANGO ) argenx SE – ADR (NASDAQ: ARGX ) Arcus Biosciences Inc (NYSE: RCUS ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) Assertio Holdings Inc (NASDAQ: ASRT ) Bausch Health Companies Inc (NYSE: BHC ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Celcuity Inc (NASDAQ: CELC ) Cellular Biomedicine Group Inc (NASDAQ: CBMG ) ChemoCentryx Inc (NASDAQ: CCXI ) Chimerix Inc (NASDAQ: CMRX ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Corcept Therapeutics Incorporated (NASDAQ: CORT ) DarioHealth Corp (NASDAQ: DRIO ) Edap Tms SA (NASDAQ: EDAP ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evogene Ltd (NASDAQ: EVGN ) Eyenovia Inc (NASDAQ: EYEN ) Glaukos Corp (NYSE: GKOS ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Haemonetics Corporation (NYSE: HAE ) Fulgent Genetics Inc (NASDAQ: FLGT ) Halozyme Therapeutics, Inc.
The Daily Biotech Pulse: Fluidigm's Saliva-Based COVID Test Approved In Europe, China Backs Amarin's Vascepa 2021/01/22 12:22:33 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 21) Acasti Pharma Inc (NASDAQ: ACST ) Alimera Sciences Inc (NASDAQ: ALIM ) argenx SE – ADR (NASDAQ: ARGX ) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) AzurRx BioPharma Inc (NASDAQ: AZRX ) Chimerix Inc (NASDAQ: CMRX ) Edap Tms SA (NASDAQ: EDAP ) Eli Lilly And Co (NYSE: LLY ) (announced positive results for its COVID-19 antibody treatment) ESSA Pharma Inc (NASDAQ: EPIX ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Inari Medical Inc (NASDAQ: NARI ) INmune Bio Inc (NASDAQ: INMB ) ( INSM ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Inventiva ADR Representing Ord Shs (NASDAQ: IVA ) Jounce Therapeutics Inc (NASDAQ: JNCE ) Krystal Biotech Inc (NASDAQ: KRYS ) Laboratory Corp. of America Holdings (NYSE: LH ) Merus NV (NASDAQ: MRUS ) Neuronetics Inc (NASDAQ: STIM ) OncoSec Medical Inc (NASDAQ: ONCS ) (announced common stock offering) PRA Health Sciences Inc (NASDAQ: PRAH ) Precision BioSciences Inc (NASDAQ: DTIL ) Profound Medical Corp (NASDAQ: PROF ) Renalytix AI PLC (NASDAQ: RNLX ) Rhythm Pharmaceuticals Inc (NASDAQ: RYTM ) Seelos Therapeutics Inc (NASDAQ: SEEL ) Surface Oncology Inc (NASDAQ: SURF ) Syneos Health Inc (NASDAQ: SYNH ) Synlogic Inc (NASDAQ: SYBX ) Twist Bioscience Corp (NASDAQ: TWST ) Vericel Corp (NASDAQ: VCEL ) Xencor Inc (NASDAQ: XNCR ) Down In The Dumps None of the biotech/medical device/diagnostic stocks hit 52-week highs in the session.
Here's the back story behind a $100M fund raiser for Chimerix: A growing oncology pipeline | WRAL TechWire 2021/01/21 16:54:29 WRAL TechWire
RESEARCH TRIANGLE PARK - The pipeline of cancer drug developer Chimerix is growing, and the biotech has raised $100 million to support it. Durham-based
Chimerix surges following news of $100M stock offering, pricing shares | WRAL TechWire 2021/01/21 12:25:31 WRAL TechWire
DURHAM - Shares in Durham biotech Chimerix surged some 13% Wednesday on news of an $86 million stock offering - and the gains held after the firm priced shares
Chimerix Announces Pricing of Public Offering of Common Stock - Stocks News Feed 2021/01/21 01:03:00 Stocks News Feed
DURHAM, N.C., Jan. 20, 2021 (GLOBE NEWSWIRE) — Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, announced today the pricing of its underwritten public offering of 11,765,000 shares of its common stock at a price to the public of $8.50 per share. All… Read More »Chimerix Announces Pricing of Public Offering of Common Stock
Durham biotech Chimerix looks to raise as much as $86M | WRAL TechWire 2021/01/20 12:13:08 WRAL TechWire
DURHAM - Biopharmaceutical firm Chimerix is looking to raise as much as $86 million through a stock offering, the company announced Tuesday after markets closed
Global Cytomegalovirus Retinitis Market Growth Factors and Applications by 2027 with Top Key Players: Gilead Sciences, Inc., Hospira, Shire Plc, Auritec Pharmaceuticals Inc., Chimerix, Ionis Pharmaceuticals 2020/12/11 09:37:33 OpenPR
Data Bridge Market Research has recently added a concise research on the Cytomegalovirus Retinitis Market to depict valuable insights related to significant market trends driving the industry. The report features analysis based on key opportunities and challenges confronted by
RTP-based Chimerix lands priority review from FDA for its smallpox treatment | WRAL TechWire 2020/12/09 11:42:21 WRAL TechWire
RESEARCH TRIANGLE PARK - Chimerix, a Durham-based biopharmaceutical company that's developing medicines to treat cancer and other diseases, has received good
Chimerix to Present at Credit Suisse 29th Annual Healthcare Conference 2020/11/05 21:01:00 GlobeNewswire
DURHAM, N.C., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines…
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings 2020/08/09 13:05:25 Benzinga
Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus treatment/vaccine news flow supported the move to the upside. Novavax, Inc.'s (NASDAQ: NVAX ) stretched valuation got further stretched as the shares added about 20% for the week in the wake of its interim Phase 1 readout for its coronavirus vaccine candidate . Bristol-Myers Squibb Co (NYSE: BMY ) reported a beat-and-raise quarter, with the shares receiving further support from a win in the patent lawsuit over its blood thinner Eliquis. The week also saw a medical technology and two biotechs debuting on the Wall Street. Here are the key catalysts for the unfolding week. Conferences BTIG Virtual Biotechnology Conference: Aug. 10-11 Wedbush PacGrow Healthcare Virtual Conference: Aug. 11-12 PDUFA Dates The FDA is said to rule on the NDA filed by Bausch Health Companies Inc (NYSE: BHC ) for EM-100, an investigational therapy for allergic conjunctivitis.